HDAC inhibitor combination with immunotherapy can block cancers progression by improvement of immunogenicity through alter activation and function of macrophage and dendritic cells, decreasing the function of immunosuppressive effect in vivo and in vitro [12–14]. This evidence concerns the gene HDAC9 and cancer.